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Introduction: T4 lung cancer is a heterogeneous group of locally 
advanced disease. We hypothesized that patients in whom T4 lung 
cancer invaded only mediastinal fat tissue would show better prog-
nosis after surgery than patients in whom T4 disease invaded other 
organs. The present study aimed to investigate how different invasive 
features of T4 disease impacted prognosis, and what types of patients 
with T4 disease could benefit most from surgical treatment.
Methods: A nationwide registry study on lung cancer surgical 
cases during 2004 was conducted by the Japanese Joint Committee 
of Lung Cancer Registry, including registries of 11,663 cases 
within Japan. The present study analyzed 215 of these cases involv-
ing T4 structures or with ipsilateral nonprimary lobe pulmonary 
metastasis (PM).
Results: Reasons for T4 classification included invasion of only 
mediastinal tissue in 32 cases (15%), invasion of other structures in 
96 cases (45%), and ipsilateral different lobe PM in 87 cases (40%); 
among these three groups, there were no significant differences in 
survival, nodal status, and patterns of first recurrence. Multivariate 
analysis showed an age of 70 years or above (p = 0.022) and nodal 
status (p = 0.004) to be significant prognostic factors. T4N0 patients 
less than 70 years of age showed significantly better prognosis than 
those who were T4N1–2 and 70 years of age or older (p = 0.0001; 
5-year survival rate 50.3 versus 19.9%).
Conclusions: There was no significant difference in survival between 
T4 patients with only mediastinal fat invasion and those with other 
T4 organ invasion and ipsilateral different lobe PM, demonstrating 
appropriateness of the T4 category definition in the current tumor, 
node, metastasis staging system. Age and nodal status were signifi-
cant independent prognostic factors in T4 patients, and the best surgi-
cal candidates were shown to be T4N0 patients who were less than 70 
years of age and had a 5-year survival rate of more than 50%.
Key Words: T4 lung cancer, Mediastinal tissue, Pulmonary metastasis. 
(J Thorac Oncol. 2013;8: 759-765)
The T4 category of lung cancer is defined by invasion of the heart, mediastinal fat tissue, great vessels, trachea, recur-
rent laryngeal nerve, esophagus, vertebral body and carina, 
and additional nodules in ipsilateral different lobes.1 In T4 
cases, mediastinal fat tissue invasion is considered to be the 
last step before involving other mediastinal organs, such as the 
great vessels, esophagus, or trachea (Fig. 1).
We hypothesized that patients in whom T4 lung cancer 
invaded only mediastinal fat tissue would show better progno-
sis after surgery than those in whom T4 lung cancer invaded 
other organs. In the present study, we analyzed the outcomes 
of patients enrolled in the Japanese Lung Cancer Registry 
Study, who had T4 disease and underwent surgery. We also 
investigated whether surgery conferred different survival ben-
efits on different types of T4 lung cancer cases.
Patients and Methods
In 2010, the Japanese Joint Committee of Lung Cancer 
Registry conducted a nationwide retrospective registry study 
on surgical cases of primary lung cancer that had occurred 
during 2004. The study included registries of 11,663 cases 
from 253 teaching hospitals in Japan; each registry contained 
the previously described clinicopathologic profiles and 
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prognoses.2 The information collected about each tumor node 
metastasis (TNM) classification was used to reclassify each 
case according to the 7th edition of the International Union 
Against Cancer tumor, node, metastasis (TNM) staging 
system published in 2009.1
Of these cases, there were 218 surgical cases involv-
ing the neighboring T4 structures or ipsilateral nonprimary 
lobe pulmonary metastasis (PM). For the present study, three 
cases were excluded because the patients had both neighbor-
ing organ invasion and PM. The remaining 215 surgical cases 
were used in the present analysis.
statistical analysis
Survival was calculated by the Kaplan–Meier method, 
and differences in survival were determined by the log-rank 
test. Time zero was the date of surgery, and the terminal events 
were death because of cancer, noncancer, or unknown causes. 
Both univariate and multivariate analyses of prognostic factors 
were carried out using Cox proportional hazards regression 
models. Hazard ratios (HRs) and 95% confidence intervals 
were calculated. A p value less than 0.05 was considered to be 
statistically significant.
ResULts
Patient Characteristics
Table 1 shows characteristics of the 215 patients 
enrolled in the study. The patients consisted of 166 men (77%) 
and 49 women (23%), with a mean age of 65.2 years and a 
mean tumor size of 4.5 cm. The reasons for T4 disease clas-
sification included neighboring organ invasion in 128 patients 
(60%) and ipsilateral different lobe PM in 87 patients (40%). 
Among the 128 patients with T4 disease invading neighboring 
organs, 32 cases (25%) invaded only mediastinal fat tissue and 
96 (75%) invaded other anatomical structures. Six patients 
with T4 disease invading both mediastinal fat tissue and other 
structures were classified as other organs invasion group. The 
tumor cell types were adenocarcinoma in 99 (46%), squamous 
cell carcinoma in 77 (36%), and others in 39 patients (18%). 
R status was R0 in 123 (57%), R1 in 24 (11%), and R2 in 58 
patients (27%). Pathologic N status was N0 in 107 (50%), N1 
in 25 (12%), N2 in 79 (37%), and N3 in four patients (2%).
n and R status Grouped by 
Reasons for t4 Category
Table 2 shows pathologic N status grouped by involved 
T4 organs. There were no significant differences in N status 
among the three groups (p = 0.537). Table 3 demonstrates R 
status grouped by involved T4 organs. Mediastinal fat inva-
sion group showed significantly higher incidence of R0 than 
the other two groups (p = 0.017).
Univariate and Multivariate 
analyses of Prognostic Factors
Univariate and multivariate analyses of prognostic 
factors were performed by means of Cox proportional hazard 
regression models. Univariate analysis showed age (p = 0.02), 
tumor size (p = 0.007), and pathologic nodal status (p = 0.004) 
to be significant prognostic factors; however, the reason for 
T4 disease was not a significant prognostic factor (p = 0.949) 
(Table 4). Multivariate analysis showed that ages 70 years and 
FiGURe 1.  A case of pT4 disease invading the 
mediastinal fat tissue. A, CT scan (lung field window) 
showing a left upper lobe tumor with visceral pleura 
involvement. B, CT scan (mediastinal window) 
showing the tumor invading the mediastinal fat 
tissue. C, Photograph of the formalin-fixed resected 
specimen. CT, computed tomography.
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above (p = 0.022; HR = 1.516) and pathologic nodal status 
(p = 0.004; HR for N0 versus N1: 1.362; HR for N0 versus 
N2: 1.906) were significant prognostic factors (Table 5).
survival analysis
Figure 2 shows the overall survival curves of the 11,663 
surgical cases in the Japanese Lung Cancer Registry Study 
grouped by pT factors. The 3- and 5-year overall survival 
rates of patients with T4 disease after surgery were 48.3% 
and 34.5%, respectively. Figure 3 presents survival curves 
grouped by three reasons for T4 category (invasion of medi-
astinal fat, invasion of other structures, and ipsilateral differ-
ent lobe PM); the 5-year survival rates in these groups were 
36.1%, 36.2%, and 33.0%, respectively, with no significant 
between-group differences in survival. The 30-day mortality 
was 0.47% (1 of 215).
Table 6 describes types of first recurrence grouped 
by three reasons for T4 category. There was no significant 
difference in patterns of first recurrence among the three 
groups (p = 0.487).
Figure 4 shows survival curves grouped by pathologic 
nodal status; the 5-year survival rates in pN0, pN1, and pN2 
taBLe 1.  Patient Characteristics in Surgical Cases  
with Pathological T4 Disease in Japanese Lung Cancer  
Registry Study
No. of patients 215
Sex
 Male 166 (77%)
 Female 49 (23%)
Age (yr)
 Range 32–84
 Mean ± SD 65.2 ± 10.4
Tumor size (cm)
 Range 0–15
 Mean ± SD 4.5 ± 2.4
Reasons for T4 disease
 Neighboring organ invasion 128 (60%)
  Invading only mediastinal fat 32 (15%)
  Invading other structures 96 (45%)
   Great vessels 58
   Heart 21
   Esophagus 8
   Vertebra 6
   Carina 5
   Trachea 3
   Recurrent nerve 2
 Ipsilateral different lobe PM 87 (40%)
Histological subtype
 Adenocarcinoma 99 (46%)
 Squamous cell carcinoma 77 (36%)
 Others 39 (18%)
R status
 R0 123 (57%)
 R1 24 (11%)
 R2 58 (27%)
 RX (unclassified) 10 (5%)
Pathological nodal status
 N0 107 (50%)
 N1 25 (12%)
 N2 79 (37%)
 N3 4 (2%)
PM, pulmonary metastasis; SD, standard deviation.
taBLe 3.  R status by Reasons for T4 category
Reasons for T4
No. of  
Patients
R Status
p R0 (%) R1 (%) R2 (%)
Mediastinal fat invasion 32 26 (81) 2 (6) 4 (13) 0.017
Other organs invasion 94 47 (50) 16 (17) 31 (33)
Ipsilateral different  
lobe PM
79 50 (63) 6 (8) 23 (29)
Total 205 123 (60) 24 (12) 58 (28)
PM, pulmonary metastasis
taBLe 4.  Univariate Analysis of Prognostic Factors Using 
Cox Proportional Hazards Regression Models
Factors Hazard Ratio 95% CI p 
Age (per yr increase) 1.022 1.003–1.041 0.020
Sex
 Male 1.000 — —
 Female 0.675 0.441–1.032 0.069
Tumor size (per cm increase) 1.753 1.164–2.640 0.007
Reasons for T4 disease 0.949
 Mediastinal fat invasion 1.000 — —
 Other organs invasion 0.980 0.581–1.653 0.939
 Ipsilateral different lobe PM 1.042 0.619–1.753 0.877
Cell type
 Non-Sq 1.000 — —
 Sq 1.138 0.792–1.636 0.484
Pathological nodal status 0.004
 N0 1.000 — —
 N1 1.561 0.890–2.739 0.121
 N2 1.890 1.297–2.754 0.001
CI, confidence interval; Sq, squamous cell carcinoma; PM, pulmonary metastasis.
taBLe 2.  N Status by Reasons for T4 Category
Reasons for T4
No. of  
Patients
N Status
p N0 (%) N1 (%) N2 (%)
Mediastinal fat invasion 31 18 (58) 4 (13) 9 (29) 0.537
Other organs invasion 95 44 (46) 14 (15) 37 (39) —
Ipsilateral different  
lobe PM
85 45 (53) 7 (8) 33 (39) —
Total 211 107 (51) 25 (12) 79 (37) —
PM, pulmonary metastasis.
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patients were 45.0%, 27.0, and 25.0%, respectively. Patients 
with pN0 disease showed significantly better prognosis than 
those with pN2 disease (p = 0.0006). Figure 5 shows survival 
curves grouped by R status; the 5-year survival rates in R0, R1, 
and R2 patients were 41.2%, 33.3%, and 18.4%, respectively. 
Patients with R0 disease showed significantly better prognosis 
than those with R2 disease (p = 0.0002). However, there were 
no significant differences in survival between patients with R0 
and R1, and those with R1 and R2 (R0 versus R1; p = 0.5536; 
R1 versus R2; p = 0.0915).
The survival curves and 5-year survival rates of the T4 
surgical cases grouped by age (< 70 years or ≥ 70 years) and 
pathologic nodal status (N0 or N1–2) are shown in Figure 6. 
Patients without nodal involvement and less than 70 years 
of age showed significantly better prognosis than those 
with nodal involvement and were 70 years of age or older 
(p = 0.0001; 5-year survival rate 50.3% versus 19.9%).
disCUssion
According to the 7th edition of the TNM staging sys-
tem, the T4 stage includes invasion of the following adja-
cent organs: heart, mediastinal tissue, great vessels, trachea, 
taBLe 5.  Multivariate Analysis of Prognostic Factors Using 
Cox Proportional Hazards Regression Models
Factors Hazard Ratio 95% CI p 
Age (yr)
 <70 1 — —
 ≥70 1.516 1.061–2.167 0.022
Tumor size  
(per cm increase)
1.074 0.996–1.159 0.065
pN status 0.004
 pN0 1 — —
 pN1 1.362 0.767–2.420 0.291
 pN2 1.906 1.306–2.781 0.001
CI, confidence interval; pN, pathologic nodal.
FiGURe 2.  Survival curves of the 11,663 surgical 
cases in the Japanese Lung Cancer Registry Study 
grouped by pT factor International Union Against 
Cancer (IUCC)-Tumor Node Metastasis v. 7).
FiGURe 3.  Survival curves of 
patients with pT4 disease grouped 
by reasons for being classified as T4. 
NS, not significant; PM, pulmonary 
metastasis.
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recurrent laryngeal nerve, esophagus, body of vertebra, and 
carina.1 Because of this great variety in neighboring organs, 
and the small number of resected T4 cases, there have been 
few review articles describing the prognosis of a substantial 
number of resected T4 cases.3–6 Thus, the judgment for surgi-
cal indication is left to each institution.
Among the T4 diseases with neighboring structure inva-
sion, mediastinal fat tissue invasion is considered to be the last 
step before involving other T4 organs, including mediastinal 
vessels, esophagus, or trachea (Fig. 1). The complete com-
bined resection of mediastinal fat tissues adjacent to the pri-
mary tumor is technically much easier than that of other T4 
organs. Therefore, we hypothesized that T4 patients with only 
mediastinal fat invasion might have a better prognosis than 
those with other T4 organ invasion or ipsilateral nonprimary 
lobe PM. However, the results of the present study found no 
significant differences in survival among these three groups 
with T4 disease. Although the number of patients in each T4 
subset is small, these findings confirm the appropriateness 
of the definition of the T4 category in the current TNM 
staging system.
Two points constitute the prime criteria in determin-
ing the indication for resecting the neighboring organs in T4 
lung cancer patients,. One is whether complete resection is 
possible, and the other is the length of survival that can be 
expected for the T4 patient even after complete resection. The 
presence or absence of complete resection is an absolute prog-
nostic factor in lung cancer surgery. Although many previous 
reports have suggested the technical feasibility of surgery for 
T4 disease, fewer series have demonstrated long-term results 
after the extended resection.3–6 Grunenwald et al.7 suggested 
that the T4 category includes two types of disease, calling one 
potentially resectable T4 and the other definitively unresect-
able T4. The potentially resectable T4 group includes cases 
where complete resection seems possible, based on the degree 
of invasion, and a better prognosis is anticipated; this group 
includes invasion of the carina, left atrium, superior vena cava 
(SVC), and mediastinal tissue. For example, in patients having 
tumor that directly invades the SVC, the prognosis after com-
bined resection of the SVC is relatively good,8–11 with a 5-year 
survival rate of 36%.12 However, cases with invasion of the 
trachea, vertebra, and esophagus are considered to be defini-
tively unresectable T4 because reconstruction is difficult, 
surgical stress is unreasonable, the operative morbidity and 
mortality are high, and a good prognosis cannot be expected 
after the resection. Grunenwald et al.7 reported the clear iden-
tification of esophageal invasion as the worst prognostic fac-
tor,4 and most surgeons consider invasion of the esophagus, 
vertebral bodies, or trachea as contraindications to surgery.
The present study was based on a nationwide registry 
that collected 11,663 cases during 2004 from 253 major 
teaching hospitals in Japan; however, only an extremely small 
number of surgical cases involved invasion of the esophagus, 
vertebra, and trachea (n = 8 [0.07%], n = 6 [0.05%], and n = 3 
taBLe 6.  Types of First Recurrence by Reasons for T4 
category
Reasons for T4
No. of  
Patients
First Recurrent Site
pLocal 
Local + 
Distant Distant
Mediastinal fat  
invasion
18 5 (28%) 4 (22%) 9 (50%) 0.487
Other organs  
invasion
46 8 (17%) 12 (26%) 26 (57%) —
Ipsilateral different  
lobe PM
52 16 (31%) 8 (15%) 28 (54%) —
Total 116 29 (25%) 24 (21%) 63 (54%) —
PM, pulmonary metastasis.
FiGURe 4.  Survival curves of patients with 
pT4 disease grouped by pN status.
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[0.03%], respectively; Table 1). Overall survival of T4 surgical 
cases in this registration study showed better prognosis, with a 
5-year survival rate of 35.4% (Fig. 2) compared with a 5-year 
survival rate of 22% reported in the International Association 
for the Study of Lung Cancer13 staging article in 2007. These 
relatively good results for T4 surgical cases were probably 
because of the recent changes in how Japanese surgeons select 
T4 disease patients as surgical candidates, in accordance with 
the results of previous reports to determine the prognosis 
of resected T4 disease.3–7 This patient selection bias may be 
one of the reasons why there was no significant difference 
in survival among the three subgroups of T4 category in our 
study (Fig. 3). Very low surgical mortality of these T4 patients 
in this registry (1 of 215; 0.47%) may support this hypothesis.
Multivariate analysis showed that nodal status was the 
most important prognostic factor in T4 disease (Table 5), similar 
to other lung cancer patients. Surgery seemed to be contraindi-
cated in patients with mediastinal metastasis because of their 
poor prognosis (HR = 1.906; p = 0.001), as previously reported. 
In the TNM 7th edition, T4N0-1M0 was downstaged from stage 
IIIB to stage IIIA. However, the indication for N1 disease is still 
controversial, as some reports suggest a very poor prognosis 
for patients with hilar metastasis (N1). A T4N0M0 case where 
complete resection is possible is a good candidate for surgical 
treatment, as shown in Figure 4, and to perform a meticulous 
evaluation of the N factor through computed tomography scan, 
positron emission tomography scan, endobronchial ultrasound, 
or mediastinoscopy before any judgment is indispensable.4–16
In the present study, age and nodal status were revealed 
to be independent prognostic factors. T4 patients 70 years 
of age or more with any nodal involvement (N1, 2) showed 
poor prognosis, whereas T4 patients less than 70 years of 
FiGURe 5.  Survival curves of patients with pT4 
disease grouped by R status. NS, not significant.
FiGURe 6.  Survival curves of patients with 
pT4 disease grouped by age and nodal status.
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age without nodal involvement (N0) showed good prognosis, 
with a 5-year survival rate of more than 50%. 　There was no 
significant difference in the distribution of involved T4 organs 
between the group of patients who were 70 years of age or 
older and that group in which patients were less than 70 years 
of age, in the present study (data not shown). Because the 
risk–benefit ratio for extended surgical resection is very high 
in older T4 patients,3 special care must be taken to decide the 
surgical indication, especially in node-positive T4 patients 
who are more than 70 years old. In particular, the outcomes 
after resection in patients with carinal involvement reportedly 
show a high average operative mortality of 17% (range, 7%–
29%).17–21 According to the evidence-based clinical practice 
guidelines of the American College of Chest Physicians,17 it is 
recommended that surgical candidates with T4 disease should 
be very carefully selected, and surgical resection should be 
carefully undertaken only at a specialized center because of 
the limited survival and the high mortality. It is necessary for 
surgeons to collectively consider the patient’s nodal status, 
age, quality of life after resection, the presence of alternative 
treatment, the extent of surgery, and subsequent morbidity and 
mortality before performing surgery for T4 disease.
ConCLUsion
Although T4 patients with only mediastinal fat inva-
sion showed high incidence of R0 resection, there was no sig-
nificant difference in survival between T4 patients with only 
mediastinal fat invasion and those with other T4 organ inva-
sion, or ipsilateral different lobe PM, which demonstrates the 
appropriateness of the T4 category definition in the current 
TNM staging system. Patients with involvement of T4 struc-
tures should be very carefully selected for surgical resection 
because of the limited survival. Before undergoing surgery, 
patients should be subjected to careful assessment of hilar and 
mediastinal nodal involvement, particularly for those who are 
70 years of age or older. On the basis of the findings obtained 
to date, the best prognosis for T4 disease is found for T4N0 
patients who are less than 70 years of age and have a 5-year 
survival rate of more than 50%.
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